These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 13882172)

  • 21. A study of fibrinogen turnover in classical hemophilia and congenital afibrinogenemia.
    RAUSEN AR; CRUCHAUD A; McMILLAN CW; GITLIN D
    Blood; 1961 Dec; 18():710-6. PubMed ID: 14490598
    [No Abstract]   [Full Text] [Related]  

  • 22. [Preparation of fibrinogen for intravenous use at a blood transfusion station].
    BILA K; FISER I; HOVEZAK V; PRINZ M
    Probl Gematol Pereliv Krovi; 1962 May; 7():43-6. PubMed ID: 13869156
    [No Abstract]   [Full Text] [Related]  

  • 23. MODERN ASPECTS OF THE TREATMENT OF HEMOPHILIA. III.
    VANCREVELD S; MOCHTAR IA; KOPPE JG
    Can Med Assoc J; 1964 May; 90(22):1248-9. PubMed ID: 14158954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [SHORT SURVEY ON RESEARCH LEADING TO A CLARIFICATION OF HEMOPHILIA].
    KUKOWKA A
    Z Gesamte Inn Med; 1963 Aug; 18():730-8. PubMed ID: 14083669
    [No Abstract]   [Full Text] [Related]  

  • 25. [Whole blood, plasma and plasma fractions].
    HASSIG A
    Praxis; 1960 Apr; 49():379-80. PubMed ID: 13851998
    [No Abstract]   [Full Text] [Related]  

  • 26. [Plasma transfusion in hemophilia. VIII. Effect of various plasma products on hemophilia A].
    van CREVELD ; MOCHTAR IA
    Ned Tijdschr Geneeskd; 1963 Jan; 107():155-9. PubMed ID: 14023830
    [No Abstract]   [Full Text] [Related]  

  • 27. [PRESERVATION OF ANTIHEMOPHILIC GLOBULIN IN PRESERVED BLOOD].
    RUTBERG RA; MALLER AR; ABDULLAEV GM
    Probl Gematol Pereliv Krovi; 1963 Sep; 8():19-23. PubMed ID: 14119758
    [No Abstract]   [Full Text] [Related]  

  • 28. THE IMPORTANCE OF PLASMA-FRACTION I ACCORDING TO COHN IN SURGICAL DISEASES.
    IMDAHL H; EGLI H
    Bibl Haematol; 1964; 19():151-5. PubMed ID: 14266988
    [No Abstract]   [Full Text] [Related]  

  • 29. [Control of transfusional therapy in the hemophilic syndrome with the quantitative determination of factor VIII].
    DE NICOLA P; SANTANGELO G; SOARDI F
    Haematologica; 1958; 43(6):429-66. PubMed ID: 13598249
    [No Abstract]   [Full Text] [Related]  

  • 30. [Substitution therapy in haemophilia A and B with special reference to plasma levels of fibrinogen].
    Schmidt EW; Landbeck G
    Monatsschr Kinderheilkd (1902); 1972 May; 120(5):171-4. PubMed ID: 4625981
    [No Abstract]   [Full Text] [Related]  

  • 31. HIP DISARTICULATION IN A PATIENT WITH HEMOPHILIA. MANAGEMENT WITH FIBRINOGEN RICH IN FACTOR 8.
    ALBRIGHT JA; SOUTHWICK WO; BOVE JR
    JAMA; 1964 Nov; 190():548-50. PubMed ID: 14198014
    [No Abstract]   [Full Text] [Related]  

  • 32. [Case of afibrinogenemia treated without using fibrinogen].
    ROSZKOWSKI I; PRATKOWSKA J
    Ginekol Pol; 1958; 29(1):69-73. PubMed ID: 13562552
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of uncontrollable, life-threatening hemorrhage].
    Stensballe J; Lethagen S; Johansson PI
    Ugeskr Laeger; 2005 Jun; 167(25-31):2789-90. PubMed ID: 16014269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [EXPERIMENTS CONCERNING FACTOR 8. LONGEVITY OF FACTOR 8 IN VIVO AND VITRO AND THE SUBFRACTIONATION OF FIBRINOGEN SAMPLES FROM 2 DONORS].
    MOCHTAR IA; KOPPE JG; STIBBE J
    Maandschr Kindergeneeskd; 1964 Jul; 32():440-5. PubMed ID: 14228685
    [No Abstract]   [Full Text] [Related]  

  • 35. [Indications and transfusion of coagulation-active blood fractions].
    Mueller-Eckhardt C; Heinrich D; Lasch HG
    Z Prakt Anasth; 1970 Dec; 5(6):401-18. PubMed ID: 4256253
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hemophilia and other hemophilia-like diseases].
    Matsuoka S
    Nihon Rinsho; 1970 Mar; 28():Suppl:1014-5. PubMed ID: 5464417
    [No Abstract]   [Full Text] [Related]  

  • 37. Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor--clinical outcome and laboratory observations.
    Sørensen B; Ingerslev J
    Thromb Haemost; 2010 Jun; 103(6):1275-6. PubMed ID: 20431843
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
    Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
    J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemophilia management in transfusion medicine.
    Poon MC; Card R
    Transfus Apher Sci; 2012 Jun; 46(3):299-307. PubMed ID: 22503305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of blood products and factor concentrates for coagulation therapy.
    Fritsma MG
    Clin Lab Sci; 2003; 16(2):115-9. PubMed ID: 12757192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.